Dermatomyositis (DM) is a rare, autoimmune muscle and skin disease that can also affect the heart, lungs, and other organs of the body.
DM is one of several types of the Idiopathic Inflammatory Myopathies. The term “idiopathic” means no known cause.
, , Dermatomyositis, Featured, Video
We hosted Priovant Therapeutics to discuss The Valor Study, a phase 3 clinical trial for adult dermatomyositis. Learn all...
Dermatomyositis and Sun Protection, Dr. Graham makes it clear the sun can cause flares. She talks about sunscreens and...
Dr. Graham educates about the skin manifestations of myositis, sharing the various DM rashes, cosmetic cover-ups, information and tips...
, , Dermatomyositis, Featured, News, Video
Watch the recording of our fireside chat, The Power of Our Voice: FDA Listening Session for Adult Dermatomyositis, where...
View the summary of our first-ever FDA Listening Session on Adult Dermatomyositis. This was an opportunity to facilitate the...
Watch the recording with Alexion Pharmaceuticals to learn about the Flex Study to evaluate the safety and efficacy of...
Seeking ten (10) people living with Dermatomyositis who would be willing to share their personal experience in a market...
, , Dermatomyositis, Featured, Research
Myositis Support & Understanding and AllStripes are partnering to create a database that will enable new Dermatomyositis research projects!...
, , Dermatomyositis, Featured, Research
Corbus releases topline results for the phase 3 study of lenabasum in dermatomyositis. While it didn't meet the primary...
, , Dermatomyositis, Featured, Necrotizing Autoimmune Myopathy, Polymyositis, Video
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as...
, , Dermatomyositis, Featured, News, Video
Dr. Victoria Werth joined us live online for a video education session titled, "Skin findings seen with myositis autoantibodies...
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
, , Dermatomyositis, Featured, News
New locations announced July 9, 2019. DETERMINE is a double-blind, placebo-controlled 1-year study designed to test the efficacy and...
, , Dermatomyositis, Featured, News
The research found that DM patients with the anti-transcriptional intermediary factor 1 (anti-TIF1) antibody were more than three times...
"New Developments on the Role of Itch in Dermatomyositis", based on new research published in the British Journal of...
Dr. Victoria Werth, MD, presents, "Overview and new developments in Dermatomyositis." This was a live Myositis Support and Understanding...
Chronic Illness, Myositis, and Depression: The following are the comments I gave to a support group about my book,...
Did you know there are doctors who have combined training in both Dermatology and Rheumatology? These physicians are referred...
Dermatomyositis is a rare autoimmune disease, occurring in only 5-10 people per million, which is caused by the body’s...
Earn donations to Myositis Support and Understanding Association at no added cost to you.
© 2022 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.
View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.
